Medical News

RSS

Progressive Medical updates 2010 Drug Spend Analysis

Progressive Medical, Inc. announced today the release of a mid-year update to its 2010 Drug Spend Analysis. This report, which supplements the report released in April, provides clients with an update in workers' compensation medication spending from January 2010 through June 2010 and key factors that affect future expenditures, including inflation, utilization and product mix.

30 Sep 2010

Prix Galien USA committee honors life saving innovations

The Prix Galien USA committee honored innovations that are saving lives last night during the Prix Galien Awards Gala. The Pro Bono Humanum Award, the Prix Galien USA 2010 and the Prix Galien International were presented and related accomplishments celebrated.

30 Sep 2010

Agilent introduces SureSelect Kinome Target Enrichment Kit to focus next-generation sequencing studies

Agilent Technologies Inc. today introduced the SureSelect Kinome Target Enrichment Kit, enabling researchers to focus next generation sequencing studies on expressed kinases (the kinome). Researchers increasingly are looking at human kinases as a rich, proven source of biomarkers as well as potential drug targets for cancers and other diseases.

30 Sep 2010

Shire announces tender offer results

Shire plc, the global specialty biopharmaceutical company, announces that shareholders of Movetis NV have tendered 99.18% of the shares of Movetis during the initial acceptance period of the tender offer which closed on September 27, 2010. The shares tendered into the tender offer are expected to be settled on October 12, 2010.

30 Sep 2010

Concentric Medical commences TREVO Study of Stentriever technology in ischemic stroke patients

Concentric Medical, Inc., the global leader in acute ischemic stroke intervention, today announced the start of the TREVO Study. The first patients were enrolled and successfully treated at the Hospital Clinic de Barcelona by the Neuroradiology team of Drs. Juan Macho and Jordi Blasco.

30 Sep 2010

Repligen Corporation completes patient enrollment in RG2417 Phase 2b clinical trial

Repligen Corporation reported today that it has completed enrollment of patients in its Phase 2b clinical trial of RG2417, an oral formulation of uridine, in patients with bipolar depression.

30 Sep 2010

Jiangbo fourth-quarter revenues decrease 5.9% to $29.3M

Jiangbo Pharmaceuticals, Inc., a pharmaceutical company with its principal operations in the People's Republic of China, today announced financial results for its fourth quarter and fiscal year ended June 30, 2010. The Company's annual report on Form 10-K has been filed with the U.S. Securities and Exchange Commission and is available on the Company's website.

30 Sep 2010

First Edition: September 30, 2010

In today's news, McDonald's may stop providing employee health benefits unless a new health law requirement is waived.

30 Sep 2010

UN Secretary announces global strategy for women and children's health at MDG summit

At the UN Millennium Development Goals (MDG) summit in New York this week, world leaders gathered to review progress on the eight goals agreed in 2000 on alleviating world poverty and ill-health by 2015. As the summit came to a close, governments, businesses and aid organisations made commitments totaling $40bn to reach the goals, with particular emphasis on improving maternal and child health.

30 Sep 2010

ICM, University of Warsaw partner with AAAS to provide site-wide access to Science publication

Washington, D.C. and Warsaw, Poland: The Interdisciplinary Centre for Mathematical and Computational Modelling (ICM), University of Warsaw, has partnered with the American Association for the Advancement of Science (AAAS) in a national site licensing agreement to provide 922 research and scientific institutions throughout Poland with site-wide access to Science , the flagship publication of AAAS.

30 Sep 2010

sanofi-aventis announces top-line results from lixisenatide Phase III GETGOAL-L-ASIA trial for Type-2 Diabetes

Zealand Pharma A/S, the biopharmaceutical company dedicated to the discovery and development of innovative peptide-based drugs, is pleased to note that its partner, sanofi-aventis, has today announced positive top-line results of the Phase III GETGOAL-L-ASIA trial which assessed the efficacy and safety of lixisenatide, a once-daily GLP-1 receptor agonist discovered by Zealand Pharma, in combination with basal insulin.

30 Sep 2010

Legal storm brews in area of mental health protection at work

Financial rewards for damages caused by mental injury at work have increased over the past five years by as much as 700%, according to a report released today by the Mental Health Commission of Canada (MHCC). The report warns that a perfect legal storm is brewing in the area of mental health protection at work, and points to emerging responsibilities for employers to provide a psychologically safe workplace. This is timely, since October is Canada's Healthy Workplace Month and next week is Mental Illness Awareness Week.

30 Sep 2010

New approach to prevent psychotic symptoms

New research has linked psychosis with an abnormal relationship between two signalling chemicals in the brain. The findings, published in tomorrow's edition of the journal Biological Psychiatry, suggest a new approach to preventing psychotic symptoms, which could lead to better drugs for schizophrenia.

30 Sep 2010

Volunteers, families in IL, IN, NY, and PA unite to raise money and awareness about pulmonary fibrosis

The Pulmonary Fibrosis Foundation (PFF) today announced its October schedule of fundraising events as part of its ongoing national campaign to raise funds for pulmonary fibrosis (PF) research, while supporting the PFF's patient education and advocacy efforts throughout the country. The PFF has seen continued expansion of its public support throughout the United States, with more than 40 local and regional fundraisers contributing greatly to the Foundation's total of more than $800,000 in gifts this year.

30 Sep 2010

Universitat Jaume I evaluates ruthenium compounds for neurodegenerative disease treatment

The pharmaceutical division of the company Neuron BPh and the research group of Organometallic Chemistry and Homogeneous Catalysis of the Universitat Jaume I, have evaluated the possible applications of a series of ruthenium compounds for their future use in the treatment of neurodegenerative disease such as Alzheimer.

30 Sep 2010

New England Journal of Medicine praises VA’s policy on disclosure of adverse medical events

The Department of Veterans Affairs (VA) policy on disclosure of adverse medical events was praised as a "valuable resource for all health care institutions" in an article in a recent issue of the New England Journal of Medicine.

30 Sep 2010

Teva Pharmaceuticals, OncoGenex initiate SYNERGY Phase 3 trial to evaluate custirsen

Teva Pharmaceuticals Industries Ltd. and OncoGenex Pharmaceuticals, Inc. announced today the initiation of SYNERGY, a global Phase 3 trial evaluating custirsen (also known as OGX-011/TV-1011) as first line therapy for the treatment of castrate-resistant prostate cancer (CRPC).

30 Sep 2010

Men may connect strongly to publicity campaigns about depression and suicide

A recent study revealed that men might connect strongly to publicity campaigns about depression and suicide, particularly when they have options for anonymous help. In Regensburg, Germany, a two-year intervention campaign resulted in a marked drop in male suicides.

30 Sep 2010

Study suggests H2O2 can act as anti-inflammatory compound

A major blow to the free radical theory of aging, which had lead the research in aging for more than 50 years and fuels a multimillionaire anti-aging industry has just been published by Portuguese scientists from the University of Minho. According to the theory, free radicals provoke oxidative damage and this is the cause of aging.

30 Sep 2010

Women's College to build Ontario's only ambulatory hospital focused on women's health

Women's College Hospital together with The Honourable Deb Matthews, Minister of Health and Long-Term Care, and women representing Ontario's diverse communities, today announced Women's College Hospital is building Ontario's only ambulatory hospital focused on meeting the unique health care needs and priorities of women.

30 Sep 2010

Medical News

Progressive Medical updates 2010 Drug Spend Analysis

Prix Galien USA committee honors life saving innovations

Agilent introduces SureSelect Kinome Target Enrichment Kit to focus next-generation sequencing studies

Shire announces tender offer results

Concentric Medical commences TREVO Study of Stentriever technology in ischemic stroke patients

Repligen Corporation completes patient enrollment in RG2417 Phase 2b clinical trial

Jiangbo fourth-quarter revenues decrease 5.9% to $29.3M

First Edition: September 30, 2010

UN Secretary announces global strategy for women and children's health at MDG summit

ICM, University of Warsaw partner with AAAS to provide site-wide access to Science publication

sanofi-aventis announces top-line results from lixisenatide Phase III GETGOAL-L-ASIA trial for Type-2 Diabetes

Legal storm brews in area of mental health protection at work

New approach to prevent psychotic symptoms

Volunteers, families in IL, IN, NY, and PA unite to raise money and awareness about pulmonary fibrosis

Universitat Jaume I evaluates ruthenium compounds for neurodegenerative disease treatment

New England Journal of Medicine praises VA’s policy on disclosure of adverse medical events

Teva Pharmaceuticals, OncoGenex initiate SYNERGY Phase 3 trial to evaluate custirsen

Men may connect strongly to publicity campaigns about depression and suicide

Study suggests H2O2 can act as anti-inflammatory compound

Women's College to build Ontario's only ambulatory hospital focused on women's health

Exploring the nanoscale: How AFM is transforming cosmetic science

Innovating Texture and Culture in Plant-Based Foods

Advancing brain microphysiological systems (bMPS)

Latest News